Navigation Links
Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Date:1/24/2013

"Late-Stage Development fourth quarter revenues grew 15.7% year-on-year to $345 million. This increase was led by 22% growth in clinical development and 16% growth in central laboratories, which more than offset a decline in our market access services. Late-Stage Development pro forma operating margins increased 130 basis points both year-on-year and sequentially to 21.3%.  In Early Development, pro forma revenue of $216 million and pro forma operating margin of 12.0% declined modestly from the third quarter level on lower demand for discovery support services.

"Looking ahead to 2013, for the full year, we are forecasting mid- to high-single digit year-on-year revenue growth and pro forma diluted earnings per share, which exclude costs from ongoing restructuring activities, in the range of $2.85 to $3.15 (assuming foreign exchange rates remain at year-end 2012 levels).  In the first quarter of 2013, we expect revenue to be up slightly from the fourth quarter level and pro forma earnings per share to be in the range of $0.71 to $0.73 as we forecast an increase in Late-Stage Development net revenues and earnings to be off-set by seasonally-lower first quarter Early Development results." 

Consolidated Results($ in millions except EPS)4Q124Q11ChangeFY12FY11ChangeTotal Revenues

$609.1

$582.4$2,365.7

$2,236.4Less: Reimbursable Out-of-Pockets 

$46.9

$49.9$185.1

$140.5Net Revenues

$562.2

$532.5

5.6%

$2,180.6

$2,095.9

4.0%Operating Income

$43.1

$39.0

10.6%

$115.9

$180.6

(35.8%)Operating Margin

7.7%

7.3%5.3%

8.6%Net Income

$33.9

$21.1

60.3%

$94.7

$132.2

(28.3%)Diluted Earnings per Share

$0.61

$0.35

77.5%

$1.68

$2.16

(22.2%)Revenue from
'/>"/>

SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... BALTIMORE, June 9, 2011 Paragon Bioservices, Inc., ... announced today that representatives from the company will ... One-on-One Partnering Meetings being held on June 27-30 ... Convention Center. Founded in 1990, ...
... Calif. and OXFORD, Miss., June 9, 2011 ... University of Mississippi today announced the university has granted ... to a potential new therapeutic use for pterostilbene (tero-STILL-bean) ... an ultra-pure formulation of pterostilbene, a compound found in ...
Cached Medicine Technology:Paragon Bioservices to Partner and Exhibit at the 2011 BIO International Convention 2ChromaDex Licenses Additional Technology for pTeroPure® From the University of Mississippi 2ChromaDex Licenses Additional Technology for pTeroPure® From the University of Mississippi 3
(Date:7/24/2014)... a medical device or surgical implant is put inside ... Northwestern University,s Guillermo Ameer, most of the time, that ... , "You will always get an inflammatory response to ... Northwestern,s McCormick School of Engineering and Applied Science and ... "A problem with commonly used plastic materials, in particular, ...
(Date:7/24/2014)... Newark, NJ (PRWEB) July 24, 2014 ... which will give one lucky family a rent-free week ... only until August 3, 2014. Don’t miss your chance ... The sweepstakes is open to all New Jersey residents, ... Horizon BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , ...
(Date:7/24/2014)... IA (PRWEB) July 24, 2014 Members of ... Michael Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, ... Governor appointed him to the Board and that his peers ... “I want to provide the best I can for the ... I am uniquely positioned to provide a special insight to ...
(Date:7/24/2014)... performed during Jewish circumcisions that involves direct oral suction ... type 1 (HSV-1) transmissions documented in infants between 1988 ... Penn Medicine researchers and published online in the ... The reviewers, from Penn,s Center for Evidence-based ... Canada and Israel. , The practiceknown as metzitzah b,pehand ...
(Date:7/24/2014)... 24, 2014 According to market ... Models, Technology Roadmap, Forecasts and Analysis - 2018", ... expected to reach $7.7 billion by 2018 at ... Browse 102 market data tables and 30 figures ... “3D Mapping Market: Global Advancements, Business Models, Technology ...
Breaking Medicine News(10 mins):Health News:Antioxidant biomaterial promotes healing 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... increased risk for life-threatening cardiovascular diseases, people with type ... advised to monitor their blood sugar levels more than ... study. ,Researchers conducted a meta-analysis of 13 previously ... sugar levels and cardiovascular disease. Results showed that blood ...
... of glycosylated hemoglobin, or HA1c, may be an independent ... // and stroke, according to the new research. Two ... control and the development of heart disease and stroke. ... people, investigators found a 21-percent increase in cardiovascular events ...
... tends to be more severe and resistant to medical ... improvement in symptoms when a full range of medical ... patients with asthma were found to have a higher ... compared to patients without asthma. A higher proportion of ...
... used antibiotic, but new research suggests it could be ... study shows patients should not be given erythromycin along ... because it increases the risk of sudden death. ... is any association between the use of erythromycin and ...
... designed to educate parents about allergens and tobacco smoke ... say researchers .More than 900 children with ... least one indoor environmental allergen and lived in low-income ... areas suffer from the disease at a disproportionately high ...
... to a recent study researchers say the antidepressant ... symptoms of fibromyalgia in women . Duloxetine ... // norepinephrine, two of the brain’s neurotransmitters that ... chronic musculoskeletal disorder that is characterized by body ...
Cached Medicine News:
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Straight heavy shafts with 7 mm tying surface. Wide serrated handle, polished finish. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Serrated handle with polished finish. Most popular size or model. Overall length 4 inches....
Medicine Products: